Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada2Departments of Oncology, Queen's University, Kingston, Ontario, Canada3Department of Public Health Sciences, Queen's University, Kingston, On.
Departments of Oncology, Queen's University, Kingston, Ontario, Canada4Department of Surgery, Queen's University, Kingston, Ontario, Canada.
JAMA Oncol. 2015 Nov;1(8):1111-9. doi: 10.1001/jamaoncol.2015.2943.
Surgical resection is standard treatment for patients with colorectal cancer (CRC) liver metastases (LM). Limited data describe practice and outcomes among elderly patients.
To describe management and outcomes of surgical resection of CRC LM in elderly patients in routine practice.
DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study of routine clinical practices in the Canadian province of Ontario. All cases of CRC in Ontario who underwent resection of LM between January 1, 2002, and December 31, 2009, were identified using the population-based Ontario Cancer Registry and included in this study. Complete information about vital status in the Ontario Cancer Registry was available up to December 31, 2012; cause of death was available up to December 31, 2010. Final study analyses were performed March 13, 2015. Surgical resections of CRC LM were identified from hospital admission records. Pathology reports provided details regarding extent of disease and surgical procedure. Patients were classified into 3 age groups: younger than 65 years, 65 to 74 years, and 75 years or older. We describe volume of resected CRC LM as a ratio of incident cases per CRC LM resection. Use of perioperative chemotherapy was identified through linked electronic treatment and physician billing records. Preoperative and postoperative chemotherapy was defined as chemotherapy given within 16 weeks of surgery.
Overall survival and cancer-specific survival measured from time of LM resection.
We identified 1310 patients: 710 (54%) younger than 65 years; 414 (32%) 65 to 74 years; and 186 (14%) 75 years or older. Case volumes of CRC LM resection varied substantially across age groups. For patients younger than 65 years, there was 1 resection per 26 incident cases; 65 to 74 years, 1 per 38; and 75 years or older, 1 per 101 (P<.001). Patients less than 65 years of age had a mean of 2.3 lesions; 65 to 74 years, 2.0; and 75 years or older, 1.6 (P<.001). For patients younger than 65 years, mean size of the largest lesion was 4.0 cm; patients 65 to 74 years, 4.4 cm; and 75 years or older, 4.5 cm (P=.04). The likelihood patients younger than 65 years were to undergo a major liver resection of more than 3 segments was 65%; 65 to 74 years, 65%; and 75 years or older, 42% (P=.04). The percentage of patients younger than 65 years who underwent perioperative chemotherapy was 71% (501 of 710); 65 to 74 years, 57% (237 of 414); and 75 years or older, 41% (77 of 186) (P<.001). The incidence of 90-day mortality for patients younger than 65 years was 2% (11 of 710); 65 to 74 years, 5% (20 of 414); and 75 years or older, 8% (14 of 186) (P<.001). Cancer-specific survival at 5 years for patients younger than 65 years of age was 49%; 65 to 74 years, 47%; and 75 years or older, 35% (P<.001). Overall survival for patients younger than 65 years was 49%; 65 to 74 years, 44%; and 75 years or older, 28% (P<.001).
Resection of CRC LM is associated with greater risk of postoperative mortality among elderly patients despite less aggressive treatment. Although the long-term outcomes are inferior to younger patients, a substantial proportion of elderly patients will have long-term survival.
手术切除是结直肠癌(CRC)肝转移(LM)患者的标准治疗方法。有限的数据描述了老年患者的治疗方法和结果。
描述在常规实践中对老年患者行结直肠癌 LM 手术切除的管理和结果。
设计、地点和参与者:这是一项基于人群的回顾性队列研究,对加拿大安大略省的常规临床实践进行研究。使用基于人群的安大略癌症登记处,确定了 2002 年 1 月 1 日至 2009 年 12 月 31 日期间在安大略省接受 LM 切除术的所有 CRC 病例,并将这些病例纳入本研究。在 2012 年 12 月 31 日之前,安大略癌症登记处可以获得有关所有病例的完整生存状态信息;2010 年 12 月 31 日之前可以获得有关所有病例的死亡原因信息。最终的研究分析于 2015 年 3 月 13 日进行。通过住院记录确定 CRC LM 的手术切除。病理报告提供了疾病范围和手术程序的详细信息。患者被分为 3 个年龄组:小于 65 岁、65 至 74 岁和 75 岁或以上。我们将 CRC LM 的切除量描述为每例 CRC LM 切除的发病例数的比例。通过链接的电子治疗和医生计费记录来确定围手术期化疗的使用情况。术前和术后化疗是指在手术前 16 周内给予的化疗。
从 LM 切除时间开始的总生存和癌症特异性生存。
我们确定了 1310 名患者:710 名(54%)小于 65 岁;414 名(32%)65 至 74 岁;186 名(14%)75 岁或以上。CRC LM 切除的病例量在各年龄组之间差异很大。对于小于 65 岁的患者,每 26 例发病例有 1 例切除;65 至 74 岁,每 38 例有 1 例;75 岁或以上,每 101 例有 1 例(P<.001)。小于 65 岁的患者平均有 2.3 个病变;65 至 74 岁,2.0 个;75 岁或以上,1.6 个(P<.001)。对于小于 65 岁的患者,最大病变的平均大小为 4.0 cm;65 至 74 岁,4.4 cm;75 岁或以上,4.5 cm(P=.04)。小于 65 岁的患者中有 65%的人有可能接受超过 3 个节段的主要肝切除术;65 至 74 岁,65%;75 岁或以上,42%(P=.04)。小于 65 岁的患者接受围手术期化疗的比例为 71%(501 例/710 例);65 至 74 岁,57%(237 例/414 例);75 岁或以上,41%(77 例/186 例)(P<.001)。小于 65 岁的患者 90 天死亡率为 2%(11 例/710 例);65 至 74 岁,5%(20 例/414 例);75 岁或以上,8%(14 例/186 例)(P<.001)。小于 65 岁的患者 5 年癌症特异性生存率为 49%;65 至 74 岁,47%;75 岁或以上,35%(P<.001)。小于 65 岁的患者总生存率为 49%;65 至 74 岁,44%;75 岁或以上,28%(P<.001)。
尽管老年患者的治疗方法不太积极,但结直肠癌 LM 切除与术后死亡率增加相关。尽管长期结果不如年轻患者,但相当一部分老年患者将长期存活。